Rafferty Asset Management, LLC Nkarta, Inc. Transaction History

Rafferty Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$12.27 - $18.39 $1.42 Million - $2.12 Million	115,403 Added 251.82%	161,231 $2.12 Million
Q2 2022 Aug 12, 2022	BUY	$7.77 - $19.44 $356,083 - $890,896	45,828 New	45,828 $565,000
Q4 2021 Feb 10, 2022	SELL	$12.79 - $26.88 $652,494 - $1.37 Million	-51,016 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$26.67 - $38.76 $84,943 - $123,450	-3,185 Reduced 5.88%	51,016 $1.42 Million
Q2 2021 Aug 10, 2021	SELL	$23.94 - $36.68 $165,545 - $253,642	-6,915 Reduced 11.31%	54,201 $1.72 Million
Q1 2021 May 10, 2021	BUY	$31.33 - $59.61 $1.8 Million - $3.43 Million	57,476 Added 1579.01%	61,116 $2.01 Million
Q4 2020 Feb 10, 2021	BUY	$27.03 - $75.62 $98,389 - $275,256	3,640 New	3,640 $224,000

129

66.5M

173K

20K

Ticker NKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,656,800
Market Cap $119M
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.